Contrasting VectivBio (NASDAQ:VECT) & Acumen Pharmaceuticals (NASDAQ:ABOS)

Acumen Pharmaceuticals (NASDAQ:ABOS) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for Acumen Pharmaceuticals and VectivBio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	0	0	4	0	3.00
VectivBio	0	0	0	0	N/A

Acumen Pharmaceuticals currently has a consensus target price of $12.00, suggesting a potential upside of 408.47%. Given Acumen Pharmaceuticals’ higher possible upside, research analysts plainly believe Acumen Pharmaceuticals is more favorable than VectivBio.

Earnings & Valuation

This table compares Acumen Pharmaceuticals and VectivBio’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$52.37 million	($1.06)	-2.23
VectivBio	$27.34 million	N/A	-$93.74 million	N/A	N/A

Acumen Pharmaceuticals has higher earnings, but lower revenue than VectivBio.

Insider and Institutional Ownership

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 7.1% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 9.7% of VectivBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Acumen Pharmaceuticals and VectivBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-22.88%	-20.82%
VectivBio	N/A	N/A	N/A

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.